These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Innate Lymphoid Cells: A Promising New Regulator in Fibrotic Diseases. Zhang Y; Tang J; Tian Z; van Velkinburgh JC; Song J; Wu Y; Ni B Int Rev Immunol; 2016 Sep; 35(5):399-414. PubMed ID: 26222510 [TBL] [Abstract][Full Text] [Related]
7. In vivo activation of a T helper 2-driven innate immune response in lung fibrosis induced by multi-walled carbon nanotubes. Dong J; Ma Q Arch Toxicol; 2016 Sep; 90(9):2231-2248. PubMed ID: 27106021 [TBL] [Abstract][Full Text] [Related]
8. Inflammation and immunity in IPF pathogenesis and treatment. Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705 [TBL] [Abstract][Full Text] [Related]
9. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756 [TBL] [Abstract][Full Text] [Related]
10. Development of chronic lung injury and pulmonary fibrosis in mice following acute exposure to nitrogen mustard. Solopov P; Marinova M; Dimitropoulou C; Colunga Biancatelli RML; Catravas JD Inhal Toxicol; 2020 Mar; 32(4):141-154. PubMed ID: 32362214 [No Abstract] [Full Text] [Related]
11. Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. Rydell-Törmänen K; Andréasson K; Hesselstrand R; Risteli J; Heinegård D; Saxne T; Westergren-Thorsson G Lab Invest; 2012 Jun; 92(6):917-25. PubMed ID: 22469699 [TBL] [Abstract][Full Text] [Related]
12. Immune mechanisms in fibrotic interstitial lung disease. Kamiya M; Carter H; Espindola MS; Doyle TJ; Lee JS; Merriam LT; Zhang F; Kawano-Dourado L; Sparks JA; Hogaboam CM; Moore BB; Oldham WM; Kim EY Cell; 2024 Jul; 187(14):3506-3530. PubMed ID: 38996486 [TBL] [Abstract][Full Text] [Related]
13. Uncoupling between inflammatory and fibrotic responses to silica: evidence from MyD88 knockout mice. Re SL; Giordano G; Yakoub Y; Devosse R; Uwambayinema F; Couillin I; Ryffel B; Marbaix E; Lison D; Huaux F PLoS One; 2014; 9(7):e99383. PubMed ID: 25050810 [TBL] [Abstract][Full Text] [Related]
14. The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. Tabata C; Tabata R; Nakano T Clin Exp Immunol; 2010 Dec; 162(3):560-7. PubMed ID: 20846163 [TBL] [Abstract][Full Text] [Related]
15. The immunology of fibrosis: innate and adaptive responses. Wick G; Backovic A; Rabensteiner E; Plank N; Schwentner C; Sgonc R Trends Immunol; 2010 Mar; 31(3):110-9. PubMed ID: 20106721 [TBL] [Abstract][Full Text] [Related]
16. Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents. Dong J; Yu X; Porter DW; Battelli LA; Kashon ML; Ma Q Arch Toxicol; 2016 Feb; 90(2):385-402. PubMed ID: 26345256 [TBL] [Abstract][Full Text] [Related]
19. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corcetto F; Corno C; Maneschi E; Pini A; Adorini L; Vannelli GB; Maggi M; Vignozzi L J Steroid Biochem Mol Biol; 2017 Apr; 168():26-37. PubMed ID: 28115235 [TBL] [Abstract][Full Text] [Related]
20. Dehydrocostus lactone inhibits BLM-induced pulmonary fibrosis and inflammation in mice via the JNK and p38 MAPK-mediated NF-κB signaling pathways. Xiong Y; Cui X; Zhou Y; Chai G; Jiang X; Ge G; Wang Y; Sun H; Che H; Nie Y; Zhao P Int Immunopharmacol; 2021 Sep; 98():107780. PubMed ID: 34118645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]